Onconetix, Inc. (ONCO)
NASDAQ: ONCO · Real-Time Price · USD
0.6600
+0.0005 (0.08%)
At close: Feb 26, 2026, 4:00 PM EST
0.6500
-0.0100 (-1.52%)
After-hours: Feb 26, 2026, 4:11 PM EST
Onconetix Revenue
Onconetix had revenue of $303.65K in the quarter ending September 30, 2025, a decrease of -25.37%. This brings the company's revenue in the last twelve months to $1.22M, down -34.58% year-over-year. In the year 2024, Onconetix had annual revenue of $2.52M with 4,217.31% growth.
Revenue (ttm)
$1.22M
Revenue Growth
-34.58%
P/S Ratio
0.84
Revenue / Employee
$244,750
Employees
5
Market Cap
1.01M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.52M | 2.47M | 4,217.31% |
| Dec 31, 2023 | 58.47K | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ensysce Biosciences | 4.49M |
| Biodexa Pharmaceuticals | 104.90K |
| Azitra | 7.50K |
| Aditxt | 5.95K |
| Virax Biolabs Group | 2.99K |
ONCO News
- 13 days ago - Onconetix, Inc. (ONCO) M&A Call Transcript - Seeking Alpha
- 14 days ago - Onconetix to Acquire Realbotix LLC, USA-based, AI-Powered Humanoid Robotics Company - GlobeNewsWire
- 14 days ago - Realbotix Corp. Announces the Sale of Realbotix, LLC Subsidiary to a NASDAQ Listed Issuer - Business Wire
- 5 months ago - Onconetix Announces Financing Through a $12.9 Million Private Placement of Series D Preferred Stock and Warrants, Termination of Merger Agreement with Ocuvex, Inc. and Settlement of $8.8 Million Debt with Veru, Inc. - GlobeNewsWire
- 5 months ago - Joint Press Release: Onconetix and Ocuvex Announce Mutual Termination of Merger Agreement - GlobeNewsWire
- 5 months ago - Onconetix announces its subsidiary, Proteomedix, licenses manufacturing IP to Immunovia enabling them to independently produce key reagents for their pancreatic cancer test PancreaSureTM - GlobeNewsWire
- 8 months ago - Onconetix and Ocuvex Therapeutics announce execution of definitive merger agreement - GlobeNewsWire
- 9 months ago - Onconetix, Inc. Announces Positive Decision by Nasdaq Hearings Panel - GlobeNewsWire